# Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients

> **NCT01668641** · PHASE2 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 91 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** GLPG0634
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01668641
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2012-09
- **Final completion:** 2012-10
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2013-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01668641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01668641, "Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01668641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*